Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- Authors
- Faivre, Sandrine; Raymond, Eric; Boucher, Eveline; Douillard, Jean; Lim, Ho Y.; Kim, Jun S.; Zappa, Magaly; Lanzalone, Silvana; Lin, Xun; DePrimo, Samuel; Harmon, Charles; Ruiz-Garcia, Ana; Lechuga, Maria J.; Cheng, Ann Lii
- Issue Date
- 8월-2009
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- TYROSINE KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; ANTITUMOR-ACTIVITY; CANCER; SU11248; VEGF; SORAFENIB; THERAPY; TARGET
- Citation
- LANCET ONCOLOGY, v.10, no.8, pp.794 - 800
- Indexed
- SCIE
SCOPUS
- Journal Title
- LANCET ONCOLOGY
- Volume
- 10
- Number
- 8
- Start Page
- 794
- End Page
- 800
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/119547
- DOI
- 10.1016/S1470-2045(09)70171-8
- ISSN
- 1470-2045
- Abstract
- Background Hepatocellular carcinoma (HCC) tumour spread is partly dependent on neoangiogenesis. In this open-label, multicentre, phase II trial done in Europe and Asia, sunitinib, a multitargeted tyrosine-kinase inhibitor with anti-angiogenic properties, was assessed in patients with advanced unresectable HCC. Methods Between February and July, 2006, eligible patients were enrolled and treated with repeated cycles of oral sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment). The primary endpoint of this Simon two-stage phase II trial was objective response rate according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with an expected response rate of 15%. This trial is registered with ClinicalTrials.gov, number NCT00247676. Findings Of 37 patients enrolled, one (2.7%) patient experienced a confirmed partial response, giving an overall objective response rate of 2.7% (95% CI 0.1-14.2); on the basis of this, the trial did not proceed to the second stage. 13 (35%) of 37 patients achieved stable disease for over 3 months. Commonly observed grade 3 and 4 adverse events included thrombocytopenia (14 of 37; 37.8%), neutropenia (nine of 37; 24.3%), asthenia (five of 37; 13.5%), hand-foot syndrome (four of 37; 10.8%), and anaemia (four of 37; 10.8%). There were four deaths among the 37 patients (10.8%) that were possibly related to treatment. Interpretation Sunitinib showed pronounced toxicities at a dose of 50 mg/day in patients with unresectable HCC. The response rate was low, and the study did not meet the primary endpoint based on RECIST criteria. Funding Pfizer Oncology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.